License Agreement with BlueRock Therapeutics

We executed a non-exclusive license agreement with BlueRock Therapeutics (regenerative medicine company launched by Bayer and Versant Ventures) to grant iPS cell related patents as a platform technology of which we have sublicensing rights from Kyoto University.

Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing